Working together, we can bring a new level of understanding to diseases of systolic and diastolic dysfunction and make a profound and lasting impact on the lives of people with serious cardiovascular diseases.

We have formed long-standing relationships with academic and clinical researcher and patient advocacy groups to create an extended community dedicated to advancing our understanding of HCM. In 2014, we launched the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Data generated from SHaRe is a component of our precision medicine platform. Our commitment to disease area leadership continues with numerous additional initiatives, including our support of the HCM Care App, a patient education resource developed in collaboration with Duke Clinical Research Institute, the launch in 2018 of the MyoSeeds™ Research Grant Program, and a research collaboration with 23andMe, Inc., a consumer genetics and research company.

Coming together as a community.

For me, the SHaRe registry demonstrates what we can do when we come together as a community with a shared goal and a spirit of collaboration. The collective data from leading centers is producing a greater understanding of the burden of HCM on patients’ lives. And in turn, SHaRe has grown into a resource for patients to learn about the latest research and to gather for education and support.